- BMO Capital downgrades Eli Lilly (LLY -2.2%) to Market Perform from Outperform after the Phase 3 failure of Alzheimer's candidate solanezumab. Price target lowered to $64 (5% downside risk) from $91.
- Atlantic Equities cuts its rating as well, from Overweight to Neutral.
Lilly's solanezumab flop prompts downgrades
Recommended For You
About LLY Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| LLY | - | - |
| Eli Lilly and Company | ||